Drug profile · INN
monobenzone
BENOQUIN
monobenzone (BENOQUIN) is a tyrosinase inhibitor. Route of administration: topical. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — monobenzone
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
monobenzone (BENOQUIN) is a tyrosinase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
INN monobenzone
Brand BENOQUIN
Mechanism Tyrosinase inhibitor
Target Tyrosinase
Route TOPICAL
Formulation CREAM
Mechanism of action
Tyrosinase inhibitor
Primary target: Tyrosinase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is monobenzone?
monobenzone (BENOQUIN) is a tyrosinase inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for monobenzone?
BENOQUIN is a marketed brand name for monobenzone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of monobenzone?
monobenzone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.